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Transferrin saturation *(
) HDP) T  *(Ca) T!C *(K ) 1"48 *(alb *(
) 1 CProlactin) B4 :H  {$ *(Kt/V 
 Clearance multiplied by time/volume  (
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 5, 
)  
	  	 '! 1 C &4\ 	 	, ',.
 (8 !  $ 'Y K 9F8 + )  
C 
  .$ :"e  U-! 	, B4  
 	,  5, :&p  (!C  
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015/0  =P  :$ TZ ".	 (
BUN )Blood urea nitrogen '! ( 5, 
) +,!0	034/0  =P\	  
,p	  ( 
 
) 042/0  =P\	 ( 
  .:$ W5&  
 *'! 1 C X\!  	,  5,
 *1H. *1D *1)8 *: .,)  10,)
 *T  *HD *1"48 *T!C *1H. L"$
Kt/V  V".	 B4  ) :$050/0 > P(.  
  
 1	
 . 	 	   	  	! " #$$% &%
 ' 	( )"	(* 	  
	    	± 	   
 )*(kg) 50 102 2/12 ± 5/67 
 -(cm) 150 185 0/9 ± 9/168 
 ./% ) 0$- 1./ !2.  3 4(mmHg) 100 190 0/24 ± 2/137 
 ./% ) 67 1./ !2.  3 4(mmHg) 90 180 5/21 ± 3/127 
 ./% ) 0$- 1./ !%  3 4(mmHg) 50 110 8/13 ± 3/76 
 ./% ) 67 1./ !%8  3 4(mmHg) 50 100 1/12 ± 3/75 
 9./ 7 : "(mg/dl) 6 14 0/2 ± 4/10 
#%;< =" 21 48 3/6 ± 8/33 
*  ./% ) 0$- > (mg/dl) 35 115 7/105 ± 4/143 
*   ./% ) 67 (mg/dl) 6 92 6/24 ± 7/33 
 .?*;.=   " (pg/ml) 17 1347 0/376 ± 6/434 
* #$2 ./% @  
 ;2< > 28 89 8/10 ± 9/64 
) 9"Bµg/dl( 30 2215 3/707 ± 2/777 
/D= 9"B #.4;E ) 9%;2;= 7µg/dl( 15 3159 8/879 ± 3/1094 
) 9.!%;4µg/dl( 20 1091 5/488 ± 4/571 
9%;2;= F$
 8 182 0/32 ± 6/42  
 ;24 (mg/dl) 2 25 0/3 ± 6/5 
 9. $/B (g/l) 4 8 7/0 ± 5/4 
 G.!(meq/l) 4 7 7/0 ± 03/5 
 G.2< (mg/dl) 7 11 6/0 ± 95/8 
 9.!<H*;(ng/ml) 3 468 1/1 ± 188 
./% #%< #$2 )Kt/V( 69/0 5/1 2/73 ± 7/102 
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 2$, -.(/ "	 0	123 . 	   	! " )"	(* " 45$  
	    	± 	  
E 6 ;	J 0 28 70/9 ± 40/10 
;	J1.:  0 10 25/3 ± 50/3 
2KL 0%= 1 10 40/2 ± 22/4 
M7 ) >K!%N > 2KL 0 14 07/4 ± 50/4 
< >K!%N 0 10 90/2 ± 31/4 
OL < >K7 0 71 62/22 ± 83/25 
  
 3	 . 78 95:(4 Spearman )' 4$ " 4*  	




&*+ #$%  
 #$%
,-	.  
&'() 	/  
 0 1(	2
3  1&'()  
&% 1(	2  4) &% 1(  
 !	"
1	5  
C.C   P  C.C   P C.C   P C.C   P  C.C   P  C.C   P  
9 489/0-  001/0 < 415/0- 001/0 440/0- 001/0 < 396/0- 002/0 362/0- 005/0 496/0- 001/0 < 
Pre-SBP   173/0 187/0 270/0 037/0 151/0 251/0 191/0 144/0 315/0 015/0 220/0 094/0 
Pre-DBP 087/0 507/0 143/0 276/0 099/0 451/0 103/0 435/0 080/0 546/0 108/0 415/0 
Prolactin  153/0 245/0 068/0 605/0 008/0 954/0 078/0 551/0 023/0 864/0 056/0 676/0 
Hb 158/0- 227/0 092/0- 484/0 203/0- 119/0 108/0- 412/0 183/0- 166/0 165/0- 213/0 
Ferritin 164/0 210/0 208/0 112/0 114/0 386/0 151/0 248/0 213/0 105/0 185/0 161/0 
Ca 046/0 730/0 043/0 747/0 085/0 517/0 029/0 826/0 008/0 949/0 077/0 563/0 
P 011/0 934/0 074/0- 572/0 007/0 958/0 085/0- 518/0 040/0- 764/0 026/0- 843/0 
PTH 272/0 042/0 146/0 068/0 174/0 199/0 240/0 075/0 288/0 031/0 267/0 047/0 
Alb 017/0 902/0 081/0 553/0 057/0 678/0 021/0 875/0 150/0- 712/0 058/0- 670/0 
Pre-BUN 143/0- 267/0 169/0- 196/0 134/0- 307/0 067/0- 203/0 120/0- 366/0 196/0- 137/0 
Post-BUN 244/0- 060/0 274/0- 034/0 177/0- 177/0 263/0- 042/0 156/0- 237/0 275/0 035/0 
URR 237/0 068/0 248/0 056/0 182/0 164/0 241/0 064/0 143/0 279/0 246/0 061/0 
Kt/V 236/0 172/0 309/0 071/0 164/0 346/0 234/0 176/0 135/0 438/0 265/0 123/0 
Duration 001/0 994/0 001/0 <  000/1 095/0 471/0 033/0- 801/0 108/0- 414/0 003/0 981/0 
C.C: Correlation coefficient ( !2$" Q%;NR ); Pre-SBP: Systolic blood pressure; Pre-DBP: Pre dialysis blood pressure 
Hb: Hemoglobin; Alb: Albumin; Pre-BUN: Pre dialysis blood urea nitrogen; Post-BUN: Post dialysis blood urea nitrogen 
URR: Urea reduction ratio; Kt/V: Clearance multiplied by time/volume; PTH: Parathyroid hormone 
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Abstract 
Background: Sexuality disorders and infertility are common in hemodialysis patients and may be due 
to hormonal disorders, uremic milieu, drugs effect and psychological problems. The aim of this study 
was the evaluation of association between sexuality disorders and some demographic and laboratory 
indices in hemodialysis patients.  
Methods: In a cross-sectional study, 60 male hemodialysis patients in Chahar Mahal va Bakhtiari 
Province, southwest of Iran, were studied. Demographic criteria including age, blood pressure, and 
laboratory findings such as before and after dialysis serum blood urea nitrogen (BUN), parathyroid 
hormone (PTH), Ca, P, K, prolactin, Fe, total iron binding capacity (TIBC), and ferritin levels and 
dialysis efficacy index (Clearance multiplied by time/volume or Kt/V) were obtained for all participants. 
Sexually function was evaluated using International index of erectile function-15 (IIEF-15) check-list. 
Findings: Mean age of the patients was 58.9 ± 19.9 years. The patients had significant disorders in all 
aspects of sexually functions including erectile function, orgasmic function, sexual desire, intercourse 
satisfaction and overall satisfaction (P < 0.05 for all). Sexually function decreased significantly with 
increasing age. Serum PTH level was inversely correlated with erectile function and overall sexual 
satisfaction. Post dialysis BUN was associated with orgasmic dysfunction and intercourse satisfaction 
problem. In addition, pre-dialysis systolic blood pressure was inversely correlated with orgasmic 
function and overall intercourse satisfaction. 
Conclusion: Our findings showed that in hemodialysis patients, control of hyperparathyroidism and 
blood pressure, and increasing of dialysis efficacy may lead to improvement of sexually function in 
hemodialysis patients. 
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